Fludarabine
Mesothelioma
National Cancer Institute (NCI)Small moleculePhase 2Active
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 48/ 100
- Competitive Position
- 81/ 100
Competitive context
55 Active assets in the Mesothelioma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cyclophosphamide National Cancer Institute (NCI) | Phase 2 | BB |
Nivolumab Orion Corporation, Orion Pharma | Phase 2 | B |
Pembrolizumab Genmab | Phase 2 | B |
18f-fspg Andrei Iagaru | Phase 2 | B |
FLUDEOXYGLUCOSE National Cancer Institute (NCI) | Phase 2 | B |
View all 50 →
Same molecule, other indications
Fludarabine is also rated in:
acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative ·
76 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →